

In the News

Update to Filgrastim Product Coverage for Medical Mutual Plans

Effective November 1, 2018, all filgrastim products, excluding the preferred product*, will be considered non-preferred. Medical Mutual will require a trial of the preferred product first. Filgrastim is a colony stimulating agent used to treat certain types of neutropenia by stimulating stem cells in bone marrow to produce more white blood cells.

The preferred filgrastim product for Medical Mutual plans (Commercial, ACA, and Medicare Advantage Plans) is noted on the left side of the table below. For more information, please visit Provider.Medmutual.com, [Tools and Resources](#), [Care Management](#), [Corporate Medical Policies](#).

Preferred Product*	Non-Preferred Products
Zarxio	<ul style="list-style-type: none">• Neupogen• Nivestym

*Preferred Products are subject to any benefit limitation set forth in the member's benefit certificate